Toggle Dropdown
Announcements
Projects
Welcome guest
Log in
Loading
Loading...
https://www.targetedonc.com/view/results-from-the-phase-3-nrg-rtog-1112-study-of-sorafenib-in-hcc
0
0
Results From the Phase 3 NRG/RTOG 1112 Study of Sorafenib in HCC - Targeted Oncology
1/20/23 at 7:00pm
Organization
Targetedonc.com
Authors
Laura Dawson
MD
Details
42 words
Summarize
Cancer
Science
Phase 3 NRG
RTOG 1112 Study of Sorafenib
sorafenib
body radiation therapy
Laura A. Dawson
FRCPC
HCC
RTOG 1112
Laura A. Dawson, MD, FRCPC, discusses findings from the NRG/RTOG 1112 study of stereotactic body radiation therapy followed by sorafenib vs sorafenib alone in hepatocellular carcinoma.
Show more
Create an account
or
login
to join the discussion
Modal title
...
Profile
Loading profile
Loading...